Department of Cardiology, University Heart Center, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Division of Angiology, Department of Medicine II, Medical University of Vienna, Vienna, Austria.
Eur J Clin Invest. 2019 Sep;49(9):e13154. doi: 10.1111/eci.13154. Epub 2019 Jul 16.
Combining high-sensitivity cardiac Troponin T (hs-cTnT), NT-pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hs-CRP) may improve risk stratification of patients with pulmonary embolism (PE) beyond the PESI risk score.
In the prospective multicentre SWITCO65+ study, we analysed 214 patients ≥ 65 years with a new submassive PE. Biomarkers and clinical information for the PESI risk score were ascertained within 1 day after diagnosis. Associations of hs-TnT, NT-proBNP, hs-CRP and the PESI risk score with the primary endpoint defined as 6-month mortality were assessed. The discriminative power of the PESI risk score and its combination with hs-cTnT, NT-proBNP and hs-CRP for 6-month mortality was compared using integrated discrimination improvement (IDI) index and net reclassification improvement (NRI).
Compared with the lowest quartile, patients in the highest quartile had a higher risk of death during the first 6 months for hs-cTnT (adjusted HR 10.22; 95% CI 1.79-58.34; P = 0.009) and a trend for NT-proBNP (adjusted HR 4.3; 95% CI 0.9-20.41; P = 0.067) unlike hs-CRP (adjusted HR 1.97; 95% CI 0.48-8.05; P = 0.344). The PESI risk score (c-statistic 0.77 (95% CI 0.69-0.84) had the highest prognostic accuracy for 6-month mortality, outperforming hs-cTnT, NT-proBNP and hs-CRP (c-statistics of 0.72, 0.72, and 0.54), respectively. Combining all three biomarkers had no clinically relevant impact on risk stratification when added to the PESI risk score (IDI = 0.067; 95% CI 0.012-0.123; P = 0.018; NRI = 0.101 95% CI -0.099-0.302; P = 0.321).
In elderly patients with PE, 6-month mortality can adequately be predicted by the PESI risk score alone.
联合检测高敏心肌肌钙蛋白 T(hs-cTnT)、氨基末端 B 型利钠肽前体(NT-proBNP)和高敏 C 反应蛋白(hs-CRP)可能会改善肺栓塞(PE)患者的风险分层,超越 PESI 风险评分。
在前瞻性多中心 SWITCO65+研究中,我们分析了 214 例年龄≥65 岁的新发亚大面积 PE 患者。在诊断后 1 天内确定 PESI 风险评分的生物标志物和临床信息。评估 hs-TnT、NT-proBNP、hs-CRP 和 PESI 风险评分与主要终点(定义为 6 个月死亡率)之间的相关性。使用综合判别改善(IDI)指数和净重新分类改善(NRI)比较 PESI 风险评分及其与 hs-cTnT、NT-proBNP 和 hs-CRP 的组合对 6 个月死亡率的判别能力。
与最低四分位相比,最高四分位的患者在最初 6 个月内死亡风险更高,hs-cTnT(调整后的 HR 10.22;95%CI 1.79-58.34;P=0.009)和 NT-proBNP(调整后的 HR 4.3;95%CI 0.9-20.41;P=0.067)呈上升趋势,而 hs-CRP(调整后的 HR 1.97;95%CI 0.48-8.05;P=0.344)则相反。PESI 风险评分(c 统计量 0.77(95%CI 0.69-0.84)对 6 个月死亡率的预测准确性最高,优于 hs-cTnT、NT-proBNP 和 hs-CRP(c 统计量分别为 0.72、0.72 和 0.54)。当添加到 PESI 风险评分时,联合三种生物标志物对风险分层没有临床相关影响(IDI=0.067;95%CI 0.012-0.123;P=0.018;NRI=0.101 95%CI -0.099-0.302;P=0.321)。
在老年 PE 患者中,6 个月死亡率可以通过 PESI 风险评分单独进行充分预测。